The global DNA repair drugs market is expected to grow at a CAGR of 7.2% during the forecast period, from 2021 to 2030. The market is driven by the increasing incidence of cancer and stroke cases globally. The PARP inhibitors segment accounted for the largest share in the global DNA repair drugs market in 2018, followed by oncological and stroke applications. North America accounted for the largest share in terms of revenue in 2018, followed by Europe and Asia Pacific respectively.
Some Of The Growth Factors Of This Market:
- Increasing awareness about the benefits of DNA repair drugs among patients and physicians is also expected to fuel demand for these products in the near future.
- In addition, technological advancements in drug discovery and development are anticipated to provide opportunities for growth in this market over the forecast period (2017-2022) 5) Increasing research activities on novel therapeutic targets for cancer treatment are also expected to drive demand for these products over the next few years.
Industry Growth Insights published a new data on “DNA Repair Drugs Market”. The research report is titled “DNA Repair Drugs Market research by Types (PARP Inhibitors, Other), By Applications (Oncological, Stroke), By Players/Companies 4SC AG, ARCAGY/ GINECO GROUP, Bristol Myers Squibb, British Columbia Cancer Agency, Cambridge University Hospitals NHS Foundation Trust, Genentech, Georgetown University, German Breast Group, GlaxoSmithKline, Jiangsu Hengrui Medicine, Johnson & Johnson, Jonsson Comprehensive Cancer Center, Karyopharm Therapeutics, KuDOS Pharmaceuticals, National Health Service, National Institutes of Health, Tesaro”.
Scope Of The Report
Report Attributes
Report Details
Report Title
DNA Repair Drugs Market Research Report
By Type
PARP Inhibitors, Other
By Application
Oncological, Stroke
By Companies
4SC AG, ARCAGY/ GINECO GROUP, Bristol Myers Squibb, British Columbia Cancer Agency, Cambridge University Hospitals NHS Foundation Trust, Genentech, Georgetown University, German Breast Group, GlaxoSmithKline, Jiangsu Hengrui Medicine, Johnson & Johnson, Jonsson Comprehensive Cancer Center, Karyopharm Therapeutics, KuDOS Pharmaceuticals, National Health Service, National Institutes of Health, Tesaro
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global DNA Repair Drugs Market Report Segments:
The global DNA Repair Drugs market is segmented on the basis of:
Types
PARP Inhibitors, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncological, Stroke
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 4SC AG
- ARCAGY/ GINECO GROUP
- Bristol Myers Squibb
- British Columbia Cancer Agency
- Cambridge University Hospitals NHS Foundation Trust
- Genentech
- Georgetown University
- German Breast Group
- GlaxoSmithKline
- Jiangsu Hengrui Medicine
- Johnson & Johnson
- Jonsson Comprehensive Cancer Center
- Karyopharm Therapeutics
- KuDOS Pharmaceuticals
- National Health Service
- National Institutes of Health
- Tesaro
Highlights of The DNA Repair Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PARP Inhibitors
- Other
- By Application:
- Oncological
- Stroke
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the DNA Repair Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
DNA repair drugs are medications that help to fix damage to DNA. DNA repair can occur during normal cell growth and division, as well as during the process of cancer development. Damage to DNA can cause mutations, which can lead to cancer.
Some of the major companies in the dna repair drugs market are 4SC AG, ARCAGY/ GINECO GROUP, Bristol Myers Squibb, British Columbia Cancer Agency, Cambridge University Hospitals NHS Foundation Trust, Genentech, Georgetown University, German Breast Group, GlaxoSmithKline, Jiangsu Hengrui Medicine, Johnson & Johnson, Jonsson Comprehensive Cancer Center, Karyopharm Therapeutics, KuDOS Pharmaceuticals, National Health Service, National Institutes of Health, Tesaro.
The dna repair drugs market is expected to register a CAGR of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. DNA Repair Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. DNA Repair Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. DNA Repair Drugs Market - Supply Chain
4.5. Global DNA Repair Drugs Market Forecast
4.5.1. DNA Repair Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. DNA Repair Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. DNA Repair Drugs Market Absolute $ Opportunity
5. Global DNA Repair Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. DNA Repair Drugs Market Size and Volume Forecast by Type
5.3.1. PARP Inhibitors
5.3.2. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global DNA Repair Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. DNA Repair Drugs Market Size and Volume Forecast by Application
6.3.1. Oncological
6.3.2. Stroke
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global DNA Repair Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. DNA Repair Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global DNA Repair Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. DNA Repair Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global DNA Repair Drugs Demand Share Forecast, 2019-2026
9. North America DNA Repair Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America DNA Repair Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America DNA Repair Drugs Market Size and Volume Forecast by Application
9.4.1. Oncological
9.4.2. Stroke
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America DNA Repair Drugs Market Size and Volume Forecast by Type
9.7.1. PARP Inhibitors
9.7.2. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America DNA Repair Drugs Demand Share Forecast, 2019-2026
10. Latin America DNA Repair Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America DNA Repair Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America DNA Repair Drugs Market Size and Volume Forecast by Application
10.4.1. Oncological
10.4.2. Stroke
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America DNA Repair Drugs Market Size and Volume Forecast by Type
10.7.1. PARP Inhibitors
10.7.2. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America DNA Repair Drugs Demand Share Forecast, 2019-2026
11. Europe DNA Repair Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe DNA Repair Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe DNA Repair Drugs Market Size and Volume Forecast by Application
11.4.1. Oncological
11.4.2. Stroke
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe DNA Repair Drugs Market Size and Volume Forecast by Type
11.7.1. PARP Inhibitors
11.7.2. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Chanel
11.11. Europe DNA Repair Drugs Demand Share, 2019-2026
12. Asia Pacific DNA Repair Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific DNA Repair Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific DNA Repair Drugs Market Size and Volume Forecast by Application
12.4.1. Oncological
12.4.2. Stroke
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific DNA Repair Drugs Market Size and Volume Forecast by Type
12.7.1. PARP Inhibitors
12.7.2. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific DNA Repair Drugs Demand Share, 2019-2026
13. Middle East & Africa DNA Repair Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa DNA Repair Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa DNA Repair Drugs Market Size and Volume Forecast by Application
13.4.1. Oncological
13.4.2. Stroke
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa DNA Repair Drugs Market Size and Volume Forecast by Type
13.7.1. PARP Inhibitors
13.7.2. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa DNA Repair Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global DNA Repair Drugs Market: Market Share Analysis
14.2. DNA Repair Drugs Distributors and Customers
14.3. DNA Repair Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. 4SC AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. ARCAGY/ GINECO GROUP
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bristol Myers Squibb
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. British Columbia Cancer Agency
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Cambridge University Hospitals NHS Foundation Trust
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Genentech
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Georgetown University
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. German Breast Group
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. GlaxoSmithKline
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Jiangsu Hengrui Medicine
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Johnson & Johnson
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Jonsson Comprehensive Cancer Center
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Karyopharm Therapeutics
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. KuDOS Pharmaceuticals
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. National Health Service
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. National Institutes of Health
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Tesaro
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook